Download PDF
J Knee Surg 2015; 28(03): 213-222
DOI: 10.1055/s-0034-1376328
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Comparison of Efficacy and Tolerability of Hylan G-F 20 in Patients with and without Effusions at the Time of Initial Injection

Bradford S. Waddell
1   Department of Orthopedics, Orthopedic Specialists of Louisiana, Shreveport, Louisiana
,
W. Hunter Waddell
1   Department of Orthopedics, Orthopedic Specialists of Louisiana, Shreveport, Louisiana
,
David D. Waddell
1   Department of Orthopedics, Orthopedic Specialists of Louisiana, Shreveport, Louisiana
› Author Affiliations
Further Information

Publication History

02 October 2013

06 March 2014

Publication Date:
07 May 2014 (online)

    Permissions and Reprints

Abstract

An effusion at the onset of viscosupplementation has been thought to diminish the efficacy and increase adverse event rates. This study compares efficacy of hylan G-F 20 in patients with and without an effusion. Patients with knee osteoarthritis (OA) received three weekly injections of hylan G-F 20. A total of 50 patients with an effusion requiring aspiration were compared with 50 matched patients without an effusion. Outcome measurements included Western Ontario and McMaster's Universities Osteoarthritis index (WOMAC) and visual analog scale (VAS). Patients were followed for 26 weeks. Both effusion and control group VAS was significantly lowered at all time points. WOMAC scores improved (p < 0.025) at all visits in the effusion group except for WOMAC A-1 week 14. Control WOMAC scores also significantly improved at all visits (p < 0.027), except for full WOMAC and WOMAC A-1 at week 1. Neither group experienced an adverse event. Presence of an effusion at onset of viscosupplementation requiring aspiration does not negatively impact efficacy of hylan G-F 20 or increase adverse event rates.

Keywords

viscosupplementation - effusion - knee
 

  • References

  • 1 Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 2004; 50 (1) 314-326
    CrossrefPubMedGoogle Scholar
  • 2 Marino AA, Waddell DD, Kolomytkin OV , et al. Increased intercellular communication through gap junctions may contribute to progression of osteoarthritis. Clin Orthop Relat Res 2004; (422) 224-232
    PubMedGoogle Scholar
  • 3 Marshall KW. Intra-articular hyaluronan therapy. Curr Opin Rheumatol 2000; 12 (5) 468-474
    CrossrefPubMedGoogle Scholar
  • 4 Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 39: 3-9
    PubMedGoogle Scholar
  • 5 Wobig M, Bach G, Beks P , et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999; 21 (9) 1549-1562
    CrossrefPubMedGoogle Scholar
  • 6 Adams ME. An analysis of clinical studies of the use of cross linked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 20: 16-18
    PubMedGoogle Scholar
  • 7 Adams ME, Atkinson MH, Lussier AJ , et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3 (4) 213-225
    CrossrefPubMedGoogle Scholar
  • 8 Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Médicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996; 23 (9) 1579-1585
    PubMedGoogle Scholar
  • 9 Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998; 20 (3) 410-423
    CrossrefPubMedGoogle Scholar
  • 10 Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994; 55: 220-232
    CrossrefPubMedGoogle Scholar
  • 11 Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol 1999; 5: S24-S31
    PubMedGoogle Scholar
  • 12 Raynauld JP, Torrance GW, Band PA , et al; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage 2002; 10 (7) 506-517
    CrossrefPubMedGoogle Scholar
  • 13 Caborn D, Rush J, Lanzer W, Parenti D, Murray C ; Synvisc 901 Study Group. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004; 31 (2) 333-343
    PubMedGoogle Scholar
  • 14 Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001; 4: 41-52
    PubMedGoogle Scholar
  • 15 Friedman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double-blind study. J Rheumatol 1980; 7 (6) 850-856
    PubMedGoogle Scholar
  • 16 Valtonen EJ. Clinical comparison of triamcinolonehexacetonide and betamethasone in the treatment of osteoarthrosis of the knee-joint. Scand J Rheumatol Suppl 1981; 41: 1-7
    PubMedGoogle Scholar
  • 17 Cooper C, Kirwan JR. The risks of local and systemic corticosteroid administration. Baillieres Clin Rheumatol 1990; 4 (2) 305-332
    CrossrefPubMedGoogle Scholar
  • 18 Gray RG, Gottlieb NL. Intra-articular corticosteroids. An updated assessment. Clin Orthop Relat Res 1983; (177) 235-263
    PubMedGoogle Scholar
  • 19 Waddell D. Viscosupplementation: Evidence for a Mechanism of Action. Paper Presented at: Annual Meeting of the Academy of Orthopedic Surgeons; March 10–14, 2004; San Francisco, CA
    PubMedGoogle Scholar
  • 20 Waddell DD, Marino AA. Chronic knee effusions in patients with advanced osteoarthritis: implications for functional outcome of viscosupplementation. J Knee Surg 2007; 20 (3) 181-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin 2003; 19 (7) 575-580
    CrossrefPubMedGoogle Scholar
  • 22 Waddell D, Estey D, Bricker DC, Marsala A. Viscosupplementation under fluoroscopic control. Am J Med Sports 2001; 4: 237-241 , 249
    PubMedGoogle Scholar
  • 23 Waddell D, Estey D, Bricker DC. Retrospective tolerance of hylan G-F 20 using fluoroscopically-confirmed injection and effectiveness of retreatment of knee osteoarthritis. Arthritis Rheum 2001; 44 (9) S48
    CrossrefPubMedGoogle Scholar
  • 24 Altman R, Asch E, Bloch D , et al; Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29 (8) 1039-1049
    CrossrefPubMedGoogle Scholar
  • 25 Waddell DD, Marino AA. Chronic knee effusions in patients with advanced osteoarthritis: implications for functional outcome of viscosupplementation. J Knee Surg 2007; 20 (3) 181-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Jackson DW, Simon TM. Intra-articular distribution and residence time of Hylan A and B: a study in the goat knee. Osteoarthritis Cartilage 2006; 14 (12) 1248-1257
    CrossrefPubMedGoogle Scholar